Showing results (21-30 of 62) with videos related to
Sort By:
Pageof 7
Expert Opinion on Investigational Drugs|August 7, 2010
The clinical development of histone deacetylase inhibitors as targeted anticancer drugsPaul A MarksBiochimica Et Biophysica Acta|July 3, 2010
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functionsPaul A MarksThe Journal of Clinical Investigation|April 3, 2008
The American Society for Clinical Investigation--the first 100 yearsPaul A MarksCellular Signalling|March 4, 2014
Insulin activation of vacuolar protein sorting 34 mediates localized phosphatidylinositol 3-phosphate production at lamellipodia and activation of mTOR/S6K1Dianne S Hirsch, Yi Shen, Milos Dokmanovic, et al.Nature Biotechnology|January 11, 2007
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugPaul A Marks, Ronald BreslowCell Cycle (Georgetown, Tex.)|March 2, 2005
Histone deacetylase inhibitors in programmed cell death and cancer therapyPaul A Marks, Xuejun JiangNature Clinical Practice. Oncology|November 3, 2005
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acidWilliam Kevin Kelly, Paul A MarksMolecular Cancer Therapeutics|December 30, 2015
Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce HepatotoxicityHaoheng Yan, Yukinori Endo, Yi Shen, et al.Plos One|November 21, 2013
Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in miceM Khair ElZarrad, Partha Mukhopadhyay, Nishant Mohan, et al.Autophagy|August 17, 2012
Curbing autophagy and histone deacetylases to kill cancer cellsNoor Gammoh, Paul A Marks, Xuejun JiangPageof 7